Abstract:PEGylation is a well-established and clinically proven half-life extension strategy for protein delivery. Protein modification with amine-reactive poly(ethylene glycol) (PEG) generates heterogeneous and complex bioconjugate mixtures, often composed of several PEG positional isomers with varied therapeutic efficacy. Laborious and costly experiments for reaction optimization and purification are needed to generate a therapeutically useful PEG conjugate. Kinetic models which accurately predict the outcome of so-called "random" PEGylation reactions provide an opportunity to bypass extensive wet lab experimentation and streamline the bioconjugation process. In this study, we propose a protein tertiary structure-dependent reactivity model that describes the rate of protein-amine PEGylation and introduces "PEG chain coverage" as a tangible metric to assess the shielding effect of PEG chains. This structure-dependent reactivity model was implemented into three models (linear, structure-based, and machine-learned) to gain insight into how protein-specific molecular descriptors (exposed surface areas, pKa, and surface charge) impacted amine reactivity at each site. Linear and machine-learned models demonstrated over 75% prediction accuracy with butylcholinesterase. Model validation with Somavert, PEGASYS, and phenylalanine ammonia lyase showed good correlation between predicted and experimentally determined degrees of modification. Our structure-dependent reactivity model was also able to simulate PEGylation progress curves and estimate "PEGmer" distribution with accurate predictions across different proteins, PEG linker chemistry, and PEG molecular weights. Moreover, in-depth analysis of these simulated reaction curves highlighted possible PEG conformational transitions (from dumbbell to brush) on the surface of lysozyme, as a function of PEG molecular weight.

Characterization of a site-specific PEGylated analog of exendin-4 and determination of the PEGylation site.

Analysis of the Interferences in Quantitation of A Site-Specifically Pegylated Exendin-4 Analog by the Bradford Method

A Site-Specific PEGylated Analog of Exendin-4 with Improved Pharmacokinetics and Pharmacodynamics in Vivo

Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris.

Site-Directed Modification of Genetically Engineered Proteus Sp Lipase K107 Variants with A Polyethylene Glycol Derivative

C-terminal Site-Specific PEGylated Exendin-4 Analog: A Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Diabetic Db/db Mice.

Site-specific PEGylation Strategies and Suitable Modified Sites of Protein Drugs

Expression, Purification, and C-terminal Site-Specific PEGylation of Cysteine-Mutated Glucagon-Like Peptide-1

Characterization of N-terminal PEGylated Endostar

Quantitatively fine-tuning the physicochemical and biological properties of peptidic polymers through monodisperse PEGylation.

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects

Site-Specific PEGylation of Protein Drugs

Characterization of a Monopeg20000-Endostar

The Technique and Clinical Development of Site-specific PEGylated Protein Drugs

Discarded free PEG-based assay for obtaining the modification extent of pegylated proteins

The Study on PEGylation and Biological Activity of Insulinotropic Analogues

Structure-Based Site-Specific PEGylation of Fibroblast Growth Factor 2 Facilitates Rational Selection of Conjugate Sites.

Site-directed PEGylation of human basic fibroblast growth factor.

The Chromatographic Behaviour of PEGylated Protein on Cation-Exchangers

Moving Protein PEGylation from an Art to a Data Science

Modified Condition Optimization of the Pegylation of Glucagon-like Peptide-